Compare Manhattan Associates Inc (MANH) vs Neurocrine Biosciences Inc (NBIX) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Manhattan Associates Inc vs Neurocrine Biosciences Inc — how do they compare? Manhattan Associates Inc trades at $204.89 (market cap $12.06B), while Neurocrine Biosciences Inc trades at $142.44 (market cap $14.36B). The key difference: Neurocrine Biosciences Inc is the larger of the two by market cap, and Manhattan Associates Inc is trading nearer its 52-week high, Neurocrine Biosciences Inc nearer its low. Which is the better fit depends on your goals — on Pluang, investors hold Manhattan Associates Inc for 12 Days and Neurocrine Biosciences Inc for 23 Days on average.
| MANH | NBIX | |
|---|---|---|
Market Cap | $12.06B | $14.36B |
Volume | 376,150 | 1,237,180 |
Sector | Technology | Health |
52-Week High | $223.76 | $185.50 |
52-Week Low | $120.88 | $123.10 |
Typical Hold Time | 12 Days | 23 Days |
Enterprise Value | $11.93B | $14.37B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
MANH trades at $206.78, up 2.31% today, with a bullish technical outlook as it sits above key support at $205. The company shows strong profitability with a net margin of 18.67% and has beaten earnings estimates for three consecutive quarters. Recent news includes a product launch of Editions for its solutions but also ongoing legal investigations into fiduciary duties.
The outlook is cautiously optimistic given analyst consensus of Buy and a $210.50 price target, though high valuation ratios and legal overhangs present risks. Earnings growth remains the key catalyst for further upside, but investors should weigh the elevated P/E of 59.26 against potential legal and competitive pressures.
Neurocrine Biosciences (NBIX) trades at $141.25, down 1.55% on the day, with a bearish technical signal driven by moving averages. Fundamentally, the company shows strong profitability with a 20.91% net income margin and has beaten EPS estimates in recent quarters. Recent news highlights pipeline progress in Prader-Willi syndrome and executive appointments.
The outlook is supported by robust analyst consensus (86.49% buy ratings) and a $204.18 price target, but risks include execution of pipeline diversification and potential pricing pressure on key drug Ingrezza. The stock offers growth potential from expanding rare-disease assets, contingent on successful commercialization.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
No sentiment data available yet.
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Manhattan Associates Inc
Manhattan Associates, Inc. is a global leader in supply chain and omnichannel commerce software. The company provides a comprehensive suite of cloud-based and on-premise solutions for warehouse management (WMS), transportation management (TMS), and order management (OMS). MANH's technology helps retailers, wholesalers, and manufacturers manage inventory, optimize logistics, and unify the shopping experience across physical and digital channels.
Read more on MANH →About Neurocrine Biosciences Inc
Neurocrine Biosciences, Inc. is a biopharmaceutical company focused on discovering, developing, and commercializing innovative treatments for neurological, endocrine, and psychiatric disorders. The company's portfolio targets conditions such as tardive dyskinesia, endometriosis, and Parkinson's disease. NBIX leverages its expertise in neurobiology and small-molecule drug development to address diseases with significant unmet medical needs.
Read more on NBIX →
